| GI Innovation applied IND of SC GI-102, a next generation immuno-oncology, in phase 1/2 to MFDS South Korea | |
|---|---|
|
서브관리자
View : 1560
|
2024-04-08
- GI will apply IND for SC GI-102 to U.S. FDA after South Korea - GI-102 manufactured from GI’s innovation can be formed without changing dosage form ![]() [Seoul, April 08,2024] GI Innovation, an innovative new drug development company, announced that GI applied IND amendment for phase 1/2 of GI-102, a next generation immuno-oncology, including subcutaneous injection (SC) clinical trial to Ministry of Food and Drug Safety (MFDS) South Korea. The IND amendment covers adaptive clinical design, including to add SC monotherapy and ongoing combination therapies with IV GI-102 and chemotherapy. Most importantly, the subcutaneous formulation of GI-102, which utilizes similar pharmacokinetics to the intravenous formulation, was developed using in-house process development know-how, eliminating the need for royalty payments for formulation changes. Moreover, GI-102 is expected to create synergy effects as the combination partner with the blockbuster products, as Rosche(Tecentriq®), MSD(Keytruda®) and BMS(Opdivo®), which represents 50 trillion won worth market. In particular, GI-102's potent anti-cancer immune cell proliferative activity, which increases the number of immune cells by an average of sevenfold, has led to five PRs (Partial Responce) to date in patients who have failed standard of care in monotherapy dose-escalation trials, which heightens expectation for GI’s trial. "The clinical results of GI-102 monotherapy alone have attracted interest from big pharma," said Myung Ho Jang, CSO (Head of Clinical Strategy). "The development of SC in line with global development trends will further increase the technology transfer value of the drug." In addition, GI will be attending AACR 2024 in April and ASCO 2024 in May to meet with several global pharmaceutical companies. |
| Previous post | Registering patent of combination therapies for GI-101 and GI-102, with blockbuster anti-cancer drugs in U.S. |
|---|---|
| Next post | Myung-Ho Jang, the founder and CSO of GI Innovation, announces a share buyback, roughly 30,000 shares |
